| __timestamp | HUTCHMED (China) Limited | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 1499100000 |
| Thursday, January 1, 2015 | 29829000 | 1923500000 |
| Friday, January 1, 2016 | 39578000 | 2351400000 |
| Sunday, January 1, 2017 | 43277000 | 2564000000 |
| Monday, January 1, 2018 | 48645000 | 2397300000 |
| Tuesday, January 1, 2019 | 52934000 | 2503400000 |
| Wednesday, January 1, 2020 | 61349000 | 3344600000 |
| Friday, January 1, 2021 | 127125000 | 4529200000 |
| Saturday, January 1, 2022 | 136106000 | 4179100000 |
| Sunday, January 1, 2023 | 133175999 | 4650100000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Viatris Inc. and HUTCHMED (China) Limited, two prominent players, showcase contrasting strategies over the past decade. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. In contrast, HUTCHMED's expenses grew more modestly, reaching around $133 million in the same year. This disparity highlights Viatris's expansive operations compared to HUTCHMED's more streamlined approach. Notably, Viatris's SG&A expenses surged by over 200% from 2014 to 2023, while HUTCHMED's increased by nearly 400%, albeit from a much smaller base. These trends underscore the diverse strategies in managing operational costs, reflecting each company's unique market positioning and growth ambitions.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Viatris Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Viatris Inc. or CymaBay Therapeutics, Inc.
Cost of Revenue Trends: Viatris Inc. vs HUTCHMED (China) Limited
Comparing SG&A Expenses: Viatris Inc. vs ACADIA Pharmaceuticals Inc. Trends and Insights
Comparing SG&A Expenses: Viatris Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Viatris Inc. vs Veracyte, Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Galapagos NV
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited Trends and Insights
Axsome Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
CymaBay Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends